Please login to the form below

Not currently logged in
Email:
Password:

ALN-PCS

This page shows the latest ALN-PCS news and features for those working in and with pharma, biotech and healthcare.

Alnylam predicts big things for its PCSK9 inhibitor ALN-PCS

Alnylam predicts big things for its PCSK9 inhibitor ALN-PCS

Alnylam predicts big things for its PCSK9 inhibitor ALN-PCS. Genesilencing specialist says its early-stage candidate has blockbuster potential. ... The success in the ongoing phase I trial means that clinical development of ALN-PCS is now taken over by

Latest news

  • Sanofi and Regeneron start cholesterol antibody trials

    Alnylam Pharmaceuticals is now thought to be in the lead among companies trying the antisense route to PCSK9 inhibition, with a successful phase I trial of its ALN-PCS candidate reported

  • Alnylam makes further cuts to workforce

    That involves accelerating the clinical development of the company's two lead programmes - ALN-TTR for the treatment of transthyretin-mediated amyloidosis and ALN-APC for haemophilia, which are both in ... Alnylam has also recently reported progress with

  • Alnylam says gene silencing therapy works for high cholesterol

    Alnylam says gene silencing therapy works for high cholesterol. ALN-PCS trial data contributes to restored interest in RNA interference. ... Alnylam Pharmaceuticals has reported encouraging results from a phase I trial of ALN-PCS, a gene silencing

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics